Generalized Anxiety Disorder Epidemiology Forecast

DelveInsight’s ‘Generalized Anxiety Disorder (GAD) – Epidemiology Forecast – 2032’ report delivers an in-depth understanding of the historical and forecasted epidemiology of Generalized Anxiety Disorder (GAD) in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2019–2032

Generalized Anxiety disorder (GAD): Disease Understanding

Generalized Anxiety Disorder (GAD) Overview

Generalized anxiety disorder involves persistent and excessive worry that interferes with daily activities. This ongoing worry and tension may be accompanied by physical symptoms, such as restlessness, feeling on edge or easily fatigued, difficulty concentrating, muscle tension, or problems sleeping. Often the worries focus on everyday things such as job responsibilities, family health, or minor matters such as chores, car repairs, or appointments.

 

GAD can go undiagnosed because of a focus on physical symptoms and the stigma of mental illness. However, people with GAD can have meaningful lives and can function socially as well, when the anxiety level is mild-to-moderate or when they are taking some treatment.

 

The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) lists separation anxiety, selective mutism, specific phobia, social anxiety disorder (also called social phobia), panic disorder, agoraphobia, generalized anxiety, substance abuse/medication-induced anxiety, and an anxiety disorder caused by another medical condition.

 

The criteria of GAD in DSM-V include the characteristics such as feeling restless, keyed up, or on edge, fatiguing easily, difficulty concentrating or the mind going blank, irritability, increased muscle tension, difficulty falling asleep, staying asleep, or restlessness. Excessive worry and anxiety occur most of the time for at least 6 months, with at least three of the core symptoms in adults and one sign in the case of children.

 

According to the Anxiety and Depression Association of America (ADAA), GAD affects 6.8 million adults, or 3.1% of the US population in any given year. Women are twice as likely to be affected. Although the exact cause of GAD is unknown, there is evidence that biological factors, family background, and life experiences, particularly stressful ones, play a role.

Generalized Anxiety Disorder (GAD): Epidemiology

The Generalized Anxiety Disorder (GAD) epidemiology division provides insights into the historical and current patient pool and the forecast trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends, along with assumptions undertaken.

 

Key Findings

The disease epidemiology covered in the report provides historical and forecasted Generalized Anxiety Disorder epidemiology segmented as the 12-month prevalent cases of generalized anxiety disorder, gender-specific cases of generalized anxiety disorder, severity specific cases of generalized anxiety disorder, and age-specific cases of generalized anxiety disorder. The report includes the prevalent scenario of Generalized Anxiety Disorder in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

Country-wise Generalized Anxiety Disorder (GAD) Epidemiology

The epidemiology segment also provides the Generalized Anxiety Disorder epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

  • The total 12-month prevalent patient population of Generalized Anxiety Disorder in the 7MM countries was close to 16 million cases in 2021.
  • As per the estimates, the United States had the highest 12-month prevalent patient population of GAD in 2021. Among the EU5 countries, Germany had the highest 12-month prevalent patient population of GAD with more than 1.4 million cases, followed by Italy in 2021. On the other hand, the UK had the lowest 12-month prevalent patient population of GAD, close to 1.1 million cases in 2021.

Scope of the Report

  • Generalized Anxiety Disorder report covers a detailed overview explaining its causes, symptoms and classification, pathophysiology, diagnosis, and treatment patterns.
  • Generalized Anxiety Disorder Epidemiology Report and Model provide an overview of the risk factors and global trends of Generalized Anxiety Disorder in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • The report provides insight into the historical and forecasted patient pool of Generalized Anxiety Disorder in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.
  • The report helps recognize the growth opportunities in the 7MM concerning the patient population.
  • The report assesses the disease risk and burden and highlights the unmet needs of Generalized Anxiety Disorder.
  • The report provides the segmentation of the Generalized Anxiety Disorder epidemiology by 12-month prevalent cases of major depressive disorder in the 7MM.
  • The report provides the segmentation of the major depressive disorder epidemiology by gender-specific cases of Generalized Anxiety Disorder in the 7MM.
  • The report provides the segmentation of the major depressive disorder epidemiology by severity specific cases of Generalized Anxiety Disorder in the 7MM.
  • The report provides the segmentation of the major depressive disorder epidemiology by age-specific cases of Generalized Anxiety Disorder in the 7MM.

Report Highlights

  • 11-year Forecast of Generalized Anxiety Disorder epidemiology
  • 7MM Coverage
  • 12-month prevalent cases of Generalized Anxiety Disorder
  • Gender-specific cases of Generalized Anxiety Disorder
  • Severity specific cases of Generalized Anxiety Disorder
  • Age-specific cases of Generalized Anxiety Disorder

KOL Views

We interview KOLs and obtain SME’s opinions through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the indications.

Key Questions Answered

  • What are the major factors that will drive the change in the patient population in Generalized Anxiety Disorder during the forecast period (2019–2032)?
  • What are the key findings pertaining to the Generalized Anxiety Disorder epidemiology across 7MM, and which country will have the highest number of patients during the forecast period (2019–2032)?
  • What would be the total number of patients with Generalized Anxiety Disorder across the 7MM during the forecast period (2019–2032)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2019–2032)?
  • At what CAGR is the patient population expected to grow in the 7MM forecast period (2019–2032)?
  • What are the disease risk, burdens, and unmet needs of Generalized Anxiety Disorder?
  • What are the currently available treatments for Generalized Anxiety Disorder?

Reasons to buy

Generalized Anxiety Disorder (GAD) Epidemiology report will allow the user to:

  • Develop business strategies by understanding the trends shaping and driving the global Generalized Anxiety Disorder (GAD) market.
  • Quantify patient populations in the global major depressive disorder market to improve product design, pricing, and launch plans.
  • Understand the magnitude of the Generalized Anxiety Disorder (GAD) population by its 12-month prevalent cases.
  • Understand the magnitude of the Generalized Anxiety Disorder (GAD) population by its gender-specific cases.
  • Understand the magnitude of the Generalized Anxiety Disorder (GAD) population by its severity specific cases.
  • Understand the magnitude of the Generalized Anxiety Disorder (GAD) population by its relapse/refractory cases.
  • The Generalized Anxiety Disorder (GAD) Epidemiology Report and Model were written and developed by Masters and PhD level epidemiologists
  • The Generalized Anxiety Disorder (GAD) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports the data presented in the report and showcases disease trends over an 11-year forecast period using reputable sources

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

1. Key Insights

2. Report Introduction

3. Executive Summary of Generalized Anxiety Disorder

4. Disease Background and Overview

4.1. Introduction

4.2. Causes and Risk Factors

4.3. Signs and Symptoms

4.4. Pathophysiology

4.5. Diagnosis

4.6. Screening Tools

4.7. Treatment and Management of Generalized Anxiety Disorder

4.7.1. Treatment of special populations

4.7.2. Treatment Guidelines

4.7.3. National Institute for Health and Care Excellence (NICE): GAD Management

4.7.4. Treatment Recommendation Summary

5. Epidemiology and Patient Population

5.1. Key Findings

5.2. 7MM Total 12-month Diagnosed Prevalent Cases of GAD

5.3. Epidemiology of Generalized Anxiety Disorder

5.4. The United States

5.4.1. Total 12-month Diagnosed Prevalent Cases of GAD in the United States

5.4.2. Gender-specific cases of GAD in the United States

5.4.3. Age-specific cases of GAD in the United States

5.4.4. Severity-specific cases of GAD in the United States

5.5. EU-5

5.5.1. EU-5 Total 12-month Diagnosed Prevalent Cases of GAD

5.5.2. Germany

5.5.2.1. Gender-specific cases of GAD in Germany

5.5.2.2. Age-specific cases of GAD in Germany

5.5.2.3. Severity-specific cases of GAD in Germany

5.5.3. France

5.5.3.1. Gender-specific cases of GAD in France

5.5.3.2. Age-specific cases of GAD in France

5.5.3.3. Severity-specific cases of GAD in France

5.5.4. Italy

5.5.4.1. Gender-specific cases of GAD in Italy

5.5.4.2. Age-specific cases of GAD in Italy

5.5.4.3. Severity-specific cases of GAD in Italy

5.5.5. Spain

5.5.5.1. Gender-specific cases of GAD in Spain

5.5.5.2. Age-specific cases of GAD in Spain

5.5.5.3. Severity-specific cases of GAD in Spain

5.5.6. The United Kingdom

5.5.6.1. Gender-specific cases of GAD in the United Kingdom

5.5.6.2. Age-specific cases of GAD in the United Kingdom

5.5.6.3. Severity-specific cases of GAD in the United Kingdom

5.5.7. Japan

5.5.7.1. Total 12-month Diagnosed Prevalent Cases of GAD in Japan

5.5.7.2. Gender-specific cases of GAD in Japan

5.5.7.3. Age-specific cases of GAD in Japan

5.5.7.4. Severity-specific cases of GAD in Japan

6. Patient Journey of GAD

7. KOL Views

8. Unmet Needs

9. Appendix

9.1. Bibliography

9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

List of Tables

Table 1: “Normal” Worry Versus Generalized Anxiety Disorder

Table 2: Characteristics to Define GAD in DSM-V

Table 3: Evolution of the Definition of GAD in Succeeding Editions Of the DSM and ICD

Table 4: Treatment Approach to GAD

Table 5: The Stepped-care model

Table 6: Treatment Recommendations Summary

Table 7: Total 12-month Diagnosed Prevalent Cases of GAD in 7MM (2019–2032)

Table 8: Total 12-month Diagnosed Prevalent Cases of GAD in the United States (2019–2032)

Table 9: Gender-specific cases of GAD in the United States (2019–2032)

Table 10: Age-specific cases of GAD in the United States (2019–2032)

Table 11: Severity-specific cases of GAD in the United States (2019–2032)

Table 12: Total 12-month Diagnosed Prevalent Cases of GAD in EU-5 (2019–2032)

Table 13: Gender-specific cases of GAD in Germany (2019–2032)

Table 14: Age-specific cases of GAD in Germany (2019–2032)

Table 15: Severity-specific cases of GAD in Germany (2019–2032)

Table 16: Gender-specific cases of GAD in France (2019–2032)

Table 17: Age-specific cases of GAD in France (2019–2032)

Table 18: Severity-specific cases of GAD in France (2019–2032)

Table 19: Gender-specific cases of GAD in Italy (2019–2032)

Table 20: Age-specific cases of GAD in Italy (2019–2032)

Table 21: Severity-specific cases of GAD in Italy (2019–2032)

Table 22: Gender-specific cases of GAD in Spain (2019–2032)

Table 23: Age-specific cases of GAD in Spain (2019–2032)

Table 24: Severity-specific cases of GAD in Spain (2019–2032)

Table 25: Gender-specific cases of GAD in the United Kingdom (2019–2032)

Table 26: Age-specific cases of GAD in the United Kingdom (2019–2032)

Table 27: Severity-specific cases of GAD in the United Kingdom (2019–2032)

Table 28: Total 12-month Diagnosed Prevalent Cases in Japan (2019–2032)

Table 29: Gender-specific cases of GAD in Japan (2019–2032)

Table 30: Age-specific cases of GAD in Japan (2019–2032)

Table 31: Severity-specific cases of GAD in Japan (2019–2032)

List of Figures

Figure 1: Overview of GAD

Figure 2: Etiology of GAD

Figure 3: Risk factors for GAD

Figure 4: Symptoms and Behaviors Associated With Generalized Anxiety Disorder

Figure 5: Anxiety Triggers

Figure 6: Mental Disorders Screening – General Anxiety Disorder Assessment (GAD-7)

Figure 7: Mental Disorders Screening – Generalized Anxiety Disorder 2-item (GAD-2)

Figure 8: GAD Treatment Flow chart

Figure 9: Cognitive Behavioral Therapy

Figure 10: Pharmacotherapy for GAD

Figure 11: GAD Management Overview

Figure 12: Total 12-month Diagnosed Prevalent Cases of GAD in 7MM (2019–2032)

Figure 13: Total 12-month Diagnosed Prevalent Cases of GAD in the United States (2019–2032)

Figure 14: Gender-specific cases of GAD in the United States (2019–2032)

Figure 15: Age-specific cases of GAD in the United States (2019–2032)

Figure 16: Severity-specific cases of GAD in the United States (2019–2032)

Figure 17: Total 12-month Diagnosed Prevalent Cases of GAD in EU-5 (2019–2032)

Figure 18: Gender-specific cases of GAD in Germany (2019–2032)

Figure 19: Age-specific cases of GAD in Germany (2019–2032)

Figure 20: Severity-specific cases of GAD in Germany (2019–2032)

Figure 21: Gender-specific cases of GAD in France (2019–2032)

Figure 22: Age-specific cases of GAD in France (2019–2032)

Figure 23: Severity-specific cases of GAD in France (2019–2032)

Figure 24: Gender-specific cases of GAD in Italy (2019–2032)

Figure 25: Age-specific cases of GAD in Italy (2019–2032)

Figure 26: Severity-specific cases of GAD in Italy (2019–2032)

Figure 27: Gender-specific cases of GAD in Spain (2019–2032)

Figure 28: Age-specific cases of GAD in Spain (2019–2032)

Figure 29: Severity-specific cases of GAD in Spain (2019–2032)

Figure 30: Gender-specific cases of GAD in the United Kingdom (2019–2032)

Figure 31: Age-specific cases of GAD in the United Kingdom (2019–2032)

Figure 32: Severity-specific cases of GAD in the United Kingdom (2019–2032)

Figure 33: Total 12-month Diagnosed Prevalent Cases in Japan (2019–2032)

Figure 34: Gender-specific cases of GAD in Japan (2019–2032)

Figure 35: Age-specific cases of GAD in Japan (2019–2032)

Figure 36: Severity-specific cases of GAD in Japan (2019–2032)

Forward to Friend

Need A Quote